-
Mashup Score: 0Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis - 6 month(s) ago
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults these patients remain under-represented in most pivotal clinical trials. We performed a systematic review and proportion meta-analysis of prospective clinical trials and observational studies of anti-BCMA CAR-T therapy in patients with MM with the aim to determine the efficacy and safety of this therapy in older adults (≥65 years).
Source: www.geriatriconcology.netCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Real-world patient cases: CAR T-cell therapy - 6 month(s) ago
During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled ‘The ins and o…
Source: www.youtube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Biomarkers and patient eligibility for CAR T cell therapies in MM - 6 month(s) ago
During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled ‘The Ins and o…
Source: www.youtube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At our #EHA2023 symposium, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/MddYweilI3 #mmsm #CARTtherapy #myeloma https://t.co/DsMw7aoCfw
-
-
Mashup Score: 2Biomarkers and patient eligibility for CAR T-cell therapies in MM - 8 month(s) ago
During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T-cells in the real world. Here we share a presentation by Shaji Kumar, Mayo Clinic, Rochester, US, on biomarkers and eligibility for CAR T-cell therapies in multiple myeloma.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At our #EHA2023 session, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/fsv9L2jhZw #mmsm #CARTtherapy #myeloma https://t.co/lexesWhAAN https://t.co/Fsm9mCeWjY
-
-
Mashup Score: 2Real-world patient cases: CAR T-cell therapy - 8 month(s) ago
At the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint symposium on the ins and outs of CAR T-cells in the real world. Here, Doris Hansen shares a patient case.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Biomarkers and patient eligibility for CAR T-cell therapies in MM - 8 month(s) ago
During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium on the ins and outs of CAR T-cells in the real world. Here we share a presentation by Shaji Kumar, Mayo Clinic, Rochester, US, on biomarkers and eligibility for CAR T-cell therapies in multiple myeloma.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At our #EHA2023 symposium, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/fsv9L2jhZw #mmsm #CARTtherapy #myeloma https://t.co/fG52apSITT
-
-
Mashup Score: 1Improving immunotherapy for advanced prostate cancer - 11 month(s) ago
Strategically boosting CAR T cells aimed at an improved target could help improve immunotherapy efficacy in prostate cancer, according to preclinical work from Fred Hutchinson Cancer Center scientists, published in Nature Communications in April.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Improving immunotherapy for advanced prostate cancer - 11 month(s) ago
Strategically boosting CAR T cells aimed at an improved target could help improve immunotherapy efficacy in prostate cancer, according to preclinical work from Fred Hutchinson Cancer Center scientists, published in Nature Communications in April.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
This Perspective reviews recent developments in the design and use of chimeric antigen receptors in treatments for cancers and other diseases.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been approved for routine use in relapsed or refractory diffuse large B-cell lymphoma after UK data showed substantial improvement in overall survival and it was found to be cost-effective.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis https://t.co/fO900h0XcF @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #CellularTherapy #CARTTherapy https://t.co/pineBpKNy2